U54AT012307
Cooperative Agreement
Overview
Grant Description
Reveal - Research Evaluating Vagal Excitation and Anatomical Linkages
Overall Abstract
The vagus nerve is involved in normal physiology, and disturbances in vagal control have been implicated in several pathophysiological conditions. However, there is a lack of information on the physiology of this nerve in humans as well as multi-organ responses to vagal nerve stimulation (VNS), despite over 100,000 VNS implants worldwide to treat epilepsy, depression, anxiety, and gastrointestinal disorders. Likewise, very little is known about how to best optimize VNS settings for existing therapies or how to develop VNS for new therapies.
The proposed Research Evaluating Vagal Excitation and Anatomical Linkages (REVEAL) center aims to conduct groundbreaking research on the effect of VNS on four key systems: the autonomic nervous system (ANS), the cardiovascular system, the immune system, and metabolic system. The ambitious scope of the research requires the participation of eight major academic and medical institutions with over 40 participating key personnel, over 140 patients, an external advisory board (which includes patient advocates), a data and safety monitoring board, and an NIH steering committee and other NIH personnel.
REVEAL will have three aims corresponding to its cores. The Clinical Core will manage over 140 patients and clinical staff from 8 different institutions to obtain consistent data on VNS effects on ANS, the cardiovascular system, the immune system, and metabolism. The Data and Analysis Core will gather, store, and analyze data from clinical sites to produce publicly available datasets for development of VNS-based therapeutics and other research. The Administration Core will coordinate the work of the REVEAL cores and stakeholders to meet the goals of NIH SPARC's VESPA program.
Overall Abstract
The vagus nerve is involved in normal physiology, and disturbances in vagal control have been implicated in several pathophysiological conditions. However, there is a lack of information on the physiology of this nerve in humans as well as multi-organ responses to vagal nerve stimulation (VNS), despite over 100,000 VNS implants worldwide to treat epilepsy, depression, anxiety, and gastrointestinal disorders. Likewise, very little is known about how to best optimize VNS settings for existing therapies or how to develop VNS for new therapies.
The proposed Research Evaluating Vagal Excitation and Anatomical Linkages (REVEAL) center aims to conduct groundbreaking research on the effect of VNS on four key systems: the autonomic nervous system (ANS), the cardiovascular system, the immune system, and metabolic system. The ambitious scope of the research requires the participation of eight major academic and medical institutions with over 40 participating key personnel, over 140 patients, an external advisory board (which includes patient advocates), a data and safety monitoring board, and an NIH steering committee and other NIH personnel.
REVEAL will have three aims corresponding to its cores. The Clinical Core will manage over 140 patients and clinical staff from 8 different institutions to obtain consistent data on VNS effects on ANS, the cardiovascular system, the immune system, and metabolism. The Data and Analysis Core will gather, store, and analyze data from clinical sites to produce publicly available datasets for development of VNS-based therapeutics and other research. The Administration Core will coordinate the work of the REVEAL cores and stakeholders to meet the goals of NIH SPARC's VESPA program.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Place of Performance
Minnesota
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/25 to 08/31/26 and the total obligations have increased 209% from $6,996,965 to $21,646,919.
Regents Of The University Of Minnesota was awarded
REVEAL: Research on Vagal Excitation & Linkages
Cooperative Agreement U54AT012307
worth $21,646,919
from the National Institute of Allergy and Infectious Diseases in September 2022 with work to be completed primarily in Minnesota United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity SPARC VNS Endpoints from Standardized Parameters (VESPA) (U54 Clinical Trial Required).
Status
(Ongoing)
Last Modified 6/22/26
Period of Performance
9/23/22
Start Date
8/31/26
End Date
Funding Split
$21.6M
Federal Obligation
$0.0
Non-Federal Obligation
$21.6M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U54AT012307
Transaction History
Modifications to U54AT012307
Additional Detail
Award ID FAIN
U54AT012307
SAI Number
U54AT012307-3576821029
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NY00 NIH National Center for Complementary & Integrative Health
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
KABJZBBJ4B54
Awardee CAGE
0DH95
Performance District
MN-90
Senators
Amy Klobuchar
Tina Smith
Tina Smith
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $14,236,706 | 97% |
Modified: 6/22/26